Pt(ii) complexes with bidentate and tridentate pyrazolyl-containing chelators: synthesis, structural characterization and biological studies
作者:Carla Francisco、Sofia Gama、Filipa Mendes、Fernanda Marques、Isabel Cordeiro dos Santos、António Paulo、Isabel Santos、Joana Coimbra、Elisabetta Gabano、Mauro Ravera
DOI:10.1039/c0dt01785j
日期:——
A series of four Pt(II) complexes anchored by bidentate or tridentate pyrazolyl-alkylamine chelators bearing different substituents at the azolyl rings has been prepared with the aim to assess their interest in the design of novel anticancer drugs. All complexes have been fully characterized by classical analytical methods and three of them were characterized also by X-ray diffraction analysis. Their solution behavior, together with lipophilicity measurements, cell uptake, antiproliferative properties, DNA interaction have been evaluated. Albeit all the complexes were less active than cisplatin on ovarian carcinoma A2780 cell line, greatly retained their activity in the cisplatin-resistant A2780cisR cell line and presented a lower resistance factor compared to cisplatin. Moreover, the Pt(II) complexes under investigation were less prone to undergo deactivation by glutathione, believed to be the major cellular target of cisplatin that inactivates the drug by binding to it irreversibly.
为了评估四种铂(II)配合物在设计新型抗癌药物中的作用,研究人员制备了一系列铂(II)配合物,这些配合物由在唑环上具有不同取代基的双叉或三叉吡唑-烷基胺螯合剂锚定。所有复合物都通过经典分析方法进行了全面表征,其中三种还通过 X 射线衍射分析进行了表征。此外,还对它们的溶液行为、亲油性测量、细胞吸收、抗增殖特性和 DNA 相互作用进行了评估。尽管所有复合物对卵巢癌 A2780 细胞系的活性都低于顺铂,但在对顺铂耐药的 A2780cisR 细胞系中却保持了很高的活性,而且耐药因子也低于顺铂。此外,研究中的铂(II)复合物不易被谷胱甘肽失活,而谷胱甘肽被认为是顺铂的主要细胞靶标,它通过与顺铂不可逆地结合而使药物失活。